Federal Circuit Affirms Injunction Against Celltrion in Aflibercept BPCIA Litigation

Start
On March 5, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s entry of a preliminary injunction preventing Celltrion, Inc. (“Celltrion”) from launching CT-P42, its aflibercept biosimilar of EYLEA®….
By: Goodwin
Previous Story

Amerman Ginder Files Official Notice of Data Breach

Next Story

Competing Stablecoin Bills Reflect Consensus and Divergence on Key Issues